Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of all purchasers of the common stock of MAKO Surgical Corporation (“MAKO” or the “Company”) (NASDAQ:MAKO) between January 9, 2012 and May 7, 2012, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934.
MAKO markets its advanced robotic arm solution and orthopedic implants for orthopedic procedures in the United States and internationally. The Company’s RIO Robotic Arm Interactive Orthopedic (“RIO”) system and MAKOplasty applications (collectively, the “RIO system”) enable orthopedic surgeons to treat patient-specific osteoarthritic disease. The Complaint alleges that the Company and certain of its executive officers misrepresented or failed to disclose that: (a) the Company was poised to suffer a larger first-quarter loss due to higher costs and slower sales of its RIO systems; (b) utilization rates were declining for the Company’s RIO systems; (c) the Company’s 2012 outlook, provided at the start of the Class Period, lacked a reasonable basis when made; and (d), based on the foregoing, defendants’ positive statements about the Company or its outlook lacked a reasonable basis.
No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased MAKO common stock between January 9, 2012 and May 7, 2012, you have certain rights, and have until July 9, 2012 to move for lead plaintiff status. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent class member. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224, by e-mail to
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.